DoAyni's build of the FDA's own Orange Book computes a real number: Vyndaqel, Pfizer's capsule form of the heart drug tafamidis meglumine, clears the last of its three listed patents and exclusivity periods on December 19, 2026. No generic manufacturer has an approved ANDA for that ingredient yet.^[1] Read on its own, that looks like a live, near-term patent-cliff opportunity sitting in public data nobody has acted on. It is also close to irrelevant, because Pfizer got there first -- not by defending the patent, but by discontinuing the product.

The drug the December date is actually about

Vyndaqel treats transthyretin amyloid cardiomyopathy, ATTR-CM, a rare and fatal disease in which a misfolded blood protein stiffens the heart muscle. Pfizer acquired the compound through its purchase of FoldRx Pharmaceuticals in 2010, and it is dosed as four 20-milligram capsules a day.^[6] By the end of 2025, Pfizer had pulled Vyndaqel from the U.S. market entirely -- a full year before its own listed patents run out -- in favor of Vyndamax, a once-daily 61-milligram capsule of the same active molecule. The company frames the switch as patient convenience: one capsule instead of four for patients who are often already managing several other medications.^[2] The effect is that the December 19, 2026 cliff date sitting in the Orange Book now describes a drug that isn't for sale.

The drug that replaced it has its own, much longer number

Vyndamax is the actual franchise. It now carries roughly 75 percent of U.S. prescription volume in the ATTR-CM market and is the only once-daily capsule approved for the disease, with clinical data showing reduced mortality and cardiovascular hospitalization.^[3] Its own Orange Book listing carries four separate patents and exclusivity periods, the last of which -- built around a crystalline polymorph of the compound -- doesn't expire until August 31, 2035.^[1][6] That alone would have made Vyndamax a poor patent-cliff candidate for years. What happened next moved the real number even further from what any patent list, by itself, could show.

A courtroom settlement, not a patent, set the real date

Generic manufacturers had been circling since June 2023, when several companies began notifying Pfizer of ANDA filings challenging the Orange Book patents on tafamidis.^[6] On April 28, 2026, Pfizer announced it had settled patent-infringement suits, filed in the U.S. District Court for the District of Delaware, against three of those challengers -- Dexcel Pharma, Hikma Pharmaceuticals, and Cipla Ltd. The settlements let each company launch a generic Vyndamax capsule no earlier than June 1, 2031, "subject to the outcome of other litigation."^[3] Pfizer's Aamir Malik, executive vice president and chief U.S. commercial officer, called it a result recognizing "the value of our innovative science and the strength of our patents."^[4] One challenger didn't settle: a separate infringement case against Apotex Corp, in the same Delaware court, over the same patents, remains open.^[4] Apotex's case is the one loose thread that could still move the 2031 floor in either direction.

What was actually at stake

The tafamidis franchise -- Vyndamax plus the now-discontinued Vyndaqel -- generated $6.38 billion in 2025, up 17 percent from the year before, one of Pfizer's largest single products by revenue.^[5] Before the settlement, Pfizer had told investors to expect a real revenue decline beginning around 2028 or 2029, when the original expectation was that generics could arrive. After it, the company's own guidance is that U.S. Vyndamax revenue stays "relatively stable" from 2028 through mid-2031.^[3][5] At a reported U.S. list price above $250,000 a year per patient, moving that date by even a few years is worth billions.^[6]

The number a patent list can show, and the one it can't

Nothing about the Orange Book's own arithmetic is wrong. Vyndaqel really does clear its last listed patent on December 19, 2026, exactly as the public record says. But a patent list can only ever report what's been filed and published -- it has no way to record that a company quietly discontinued the product the cliff date was about, and no way to record a private courtroom settlement that resets a different product's real entry date to a number nowhere in the patent filings themselves. The public record and the real timeline agree on one thing and diverge sharply on the other. The date that actually governs $6 billion of Pfizer's revenue wasn't set by a patent examiner. It was set six months ago, in a settlement negotiation, and the only reason it's checkable at all is that Pfizer chose to put out a press release about it.